weight.

- 5. (Presently amended) The method of claim 4, wherein said noribogaine <u>or its salt</u> is administered at a dose of between 1.0 mg and 30 mg per kg of body weight.
 - 6. (Presently amended) A method of treating a patient to alleviate pain, comprising:
- a) administering systemically to said patient an amount of noribogaine <u>or its</u> pharmaceutically acceptable <u>salt;</u> and
- b) concomitantly administering systemically to said patient an amount of one or more opioid antagonists; wherein said respective amounts of noribogaine and said one or more opioid antagonists are effective to reduce or eliminate pain in said patient.
- 7. (Original) The method of claim 6, wherein said opioid antagonist is naloxone, administered to said patient at a dose between 0.05 mg and 0.5 mg for each mg of noribogaine.
- 8. (Original) The method of claim 6, wherein said opioid antagonist is naltrexone, administered to said patient at a dose of between 0.05 mg and 0.5 mg for each mg of noribogaine.
- 9. (Original) The method of claim 6, wherein said noribogaine and said opioid antagonist are administered transdermally.

Claims 10-24. Previously cancelled.

Please add the following new claims:

- 25. (New) A method of treating a patient to alleviate pain without addiction, comprising: administering systemically a pharmaceutical composition consisting essentially of an effective amount of noribogaine or its pharmaceutically acceptable salt to said patient effective to reduce or eliminate pain in said patient.
- 26. (New) The method of claim 25, wherein said noribogaine or its salt is the sole analgesic agent in said pharmaceutical composition.
 - 27. (New) The method of 25, wherein said noribogaine or its salt is administered to said